Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says

MT Newswires Live07-09 20:04

Ascendis Pharma's (ASND) strong stock performance will likely continue after a more than 30% return in the past few weeks, Wedbush analysts said in a Thursday note.

The analysts said that recent 5-year data from the phase-2 PaTH Forward study and the 182-week data from the phase-3 PaTHway study provide strong evidence of Yorvipath's unmatched efficacy and safety in treating hypoparathyroidism.

Wedbush raised its projections on the company's US market penetration by 1% each year from 2027 through 2035.

Yorvipath's worldwide revenue is now projected to reach 3.9 billion euros ($4.5 billion) in 2035, compared with a previous forecast of 3.8 billion euros.

Wedbush retained an outperform rating on the stock and increased its price target to $327 from $273.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650921821?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650921821","market":"us","top_or_hot":-1,"title":"Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Ascendis Pharma's (ASND) strong stock performance will likely continue after a more than 30% return in the past few weeks, Wedbush analysts said in a Thursday note.</p><p>The analysts said that recent 5-year data from the phase-2 PaTH Forward study and the 182-week data from the phase-3 PaTHway study provide strong evidence of Yorvipath's unmatched efficacy and safety in treating hypoparathyroidism.</p><p>Wedbush raised its projections on the company's US market penetration by 1% each year from 2027 through 2035.</p><p>Yorvipath's worldwide revenue is now projected to reach 3.9 billion euros ($4.5 billion) in 2035, compared with a previous forecast of 3.8 billion euros.</p><p>Wedbush retained an outperform rating on the stock and increased its price target to $327 from $273.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma Stock's Strong Momentum to Continue, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-09 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ascendis Pharma's (ASND) strong stock performance will likely continue after a more than 30% return in the past few weeks, Wedbush analysts said in a Thursday note.</p><p>The analysts said that recent 5-year data from the phase-2 PaTH Forward study and the 182-week data from the phase-3 PaTHway study provide strong evidence of Yorvipath's unmatched efficacy and safety in treating hypoparathyroidism.</p><p>Wedbush raised its projections on the company's US market penetration by 1% each year from 2027 through 2035.</p><p>Yorvipath's worldwide revenue is now projected to reach 3.9 billion euros ($4.5 billion) in 2035, compared with a previous forecast of 3.8 billion euros.</p><p>Wedbush retained an outperform rating on the stock and increased its price target to $327 from $273.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEDI","symbol_name":"HARBOR HEALTH CARE ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650921821","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650921821","pubTimestamp":1783598683,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ascendis Pharma's (ASND) strong stock performance will likely continue after a more than 30% return in the past few weeks, Wedbush analysts said in a Thursday note.The analysts said that recent 5-year","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MEDI":"HARBOR HEALTH CARE ETF","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ASND":"Ascendis Pharma A/S","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"韦德布什表示，Ascendis Pharma股票将继续保持强劲势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDI":0.6,"ASND":1},"content_text":"Ascendis Pharma's (ASND) strong stock performance will likely continue after a more than 30% return in the past few weeks, Wedbush analysts said in a Thursday note.The analysts said that recent 5-year data from the phase-2 PaTH Forward study and the 182-week data from the phase-3 PaTHway study provide strong evidence of Yorvipath's unmatched efficacy and safety in treating hypoparathyroidism.Wedbush raised its projections on the company's US market penetration by 1% each year from 2027 through 2035.Yorvipath's worldwide revenue is now projected to reach 3.9 billion euros ($4.5 billion) in 2035, compared with a previous forecast of 3.8 billion euros.Wedbush retained an outperform rating on the stock and increased its price target to $327 from $273.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650921821","isCrawlerRequest":true}